Filing excerpt
Acquired in-process research and development expenses were $11.3 billion for the nine months ended September 30, 2026, primarily related to the following transactions: $7.0 billion Arcellx acquisition; $3.1 billion Tubulis acquisition; $1.0 billion Ouro Medicines acquisition